Silence Therapeutics (SLN) AI Stock Analysis

• Market Cap: $307.02M
• Dividend Yield: N/A
• Average Volume (3M): 101.05K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.30
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 116
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.19
• Shares Outstanding: 47,233,948
• 10 Day Avg. Volume: 169,902
• 30 Day Avg. Volume: 101,050
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.52
• Enterprise Value/Revenue: 6.18
• Enterprise Value/Gross Profit: 7.50
• Enterprise Value/Ebitda: -2.83
• 1Y Price Target: $50.00
• Price Target Upside: 591.56% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 56 Neutral
• Price Target: $7.50 ▲(3.73% Upside)

The overall score is primarily driven by strong technical indicators suggesting bullish momentum. However, financial performance and valuation concerns, such as profitability challenges and negative equity, weigh down the score.

Positive Factors

Revenue Growth Potential

The company's business model of leveraging partnerships for revenue generation provides a scalable path for growth, especially as successful clinical trials can lead to lucrative licensing agreements.

Cash Reserves

Substantial cash reserves provide a buffer against operational challenges and offer flexibility to invest in R&D and strategic initiatives, which is crucial for a biotech firm in growth phases.

Innovative Platform

The proprietary mRNA-targeted platform positions the company at the forefront of gene therapy, addressing unmet medical needs and potentially leading to breakthrough treatments in the biotech industry.

Negative Factors

Profitability Challenges

Ongoing profitability issues, highlighted by negative EBIT and net income margins, indicate a need for improved cost management or increased revenue to achieve sustainable financial health.

Negative Stockholders' Equity

Negative stockholders' equity reflects financial instability, posing risks to long-term viability and limiting the company's ability to leverage debt for growth opportunities.

Negative Free Cash Flow

Consistently negative free cash flow indicates cash management issues, which can hinder the company's ability to fund operations and invest in future growth without relying on external financing.

Silence Therapeutics Business Overview & Revenue Model

Company Description

Silence Therapeutics (SLN) is a biotechnology company focused on developing innovative RNA interference (RNAi) therapeutics to treat a range of diseases, including liver diseases and rare disorders. The company harnesses its proprietary mRNA-targeted platform to create targeted therapies that can modulate gene expression, offering potential treatments for conditions with significant unmet medical needs. Silence Therapeutics operates primarily in the pharmaceutical sector, working on drug development and partnerships with other biotechnology firms.

How the Company Makes Money

Silence Therapeutics generates revenue primarily through collaboration agreements and partnerships with pharmaceutical companies. These collaborations typically involve upfront payments, milestone payments tied to the progression of drug candidates through clinical development, and royalties on future product sales. The company also seeks funding through grants and research contracts that support its therapeutic development programs. Additionally, advancements in its pipeline and successful clinical trial outcomes can significantly enhance its revenue potential through licensing agreements or partnerships for commercialization.

Silence Therapeutics Financial Statement Overview

Summary

Silence Therapeutics shows revenue growth but struggles with profitability, negative equity, and cash flow challenges. The financial instability is a significant concern, requiring strategic improvements in cost management and financial planning.

Income Statement

Silence Therapeutics has demonstrated significant revenue growth over the years, with a notable increase from 2023 to 2024. However, the company continues to face challenges with profitability, as evidenced by negative EBIT and net income margins. The consistent negative profit margins highlight a need for enhanced cost management or increased revenue to achieve profitability.

Balance Sheet

The company's balance sheet reveals a concerning negative stockholders' equity as of 2024, indicating financial instability. The debt-to-equity ratio is not favorable due to the negative equity, and although the company maintains substantial cash reserves, the high liabilities present a risk. Improving equity and managing liabilities are critical for financial health.

Cash Flow

Silence Therapeutics has managed significant financing cash flow, which supports its operations despite negative operating cash flow. The free cash flow has been consistently negative, reflecting ongoing cash challenges. However, the company's ability to secure financing offers some operational flexibility. Improving free cash flow is essential for sustainable growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	25.84M	43.26M	25.38M	17.50M	12.41M	5.48M
Gross Profit	21.32M	31.45M	15.06M	6.62M	4.96M	1.72M
EBITDA	-56.55M	-48.99M	-49.78M	-47.88M	-45.42M	-35.53M
Net Income	-68.72M	-45.31M	-43.27M	-40.49M	-39.41M	-32.55M
Balance Sheet
Total Assets	165.23M	202.63M	93.82M	107.50M	96.19M	85.97M
Cash, Cash Equivalents and Short-Term Investments	114.16M	147.33M	54.03M	71.14M	73.54M	37.45M
Total Debt	0.00	117.00K	272.00K	446.00K	137.00K	341.00K
Total Liabilities	71.08M	68.61M	76.77M	85.43M	87.67M	76.91M
Stockholders Equity	94.16M	134.02M	17.05M	22.07M	8.53M	9.06M
Cash Flow
Free Cash Flow	-78.77M	-67.85M	-39.40M	-45.90M	5.47M	-11.29M
Operating Cash Flow	-78.61M	-67.64M	-39.35M	-45.46M	6.81M	-10.78M
Investing Cash Flow	-6.66M	-21.97M	16.43M	-16.54M	8.68M	9.62M
Financing Cash Flow	25.86M	142.09M	25.16M	43.05M	30.71M	15.43M

Silence Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7.23
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SLN, the sentiment is Positive. The current price of 7.23 is above the 20-day moving average (MA) of 6.24, above the 50-day MA of 5.56, and above the 200-day MA of 4.99, indicating a bullish trend. The MACD of 0.56 indicates Negative momentum. The RSI at 68.25 is Neutral, neither overbought nor oversold. The STOCH value of 66.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SLN.

Silence Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SLN	―	$307.02M	―	―	―	―	―
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ABEO	―	$255.88M	7.91	48.34%	―	―	―
IMAB	―	$366.66M	―	―	―	-100.00%	72.45%
HUMA	―	$318.36M	―	―	―	―	63.92%
GALT	―	$327.35M	-7.94	―	―	―	17.80%
VOR	―	$184.20M	―	―	―	―	-686.12%

Silence Therapeutics Corporate Events

Michael Davidson Resigns from Silence Therapeutics Board

On August 11, 2025, Michael Davidson resigned from the board of directors of Silence Therapeutics plc to focus on his role as CEO of NewAmsterdam Pharma Company N.V. His departure was not due to any disagreements with the company. The board expressed gratitude for his contributions and reduced its size from five to four directors, appointing Iain Ross to fill the vacancy on the Audit and Risk Committee.

The most recent analyst rating on (SLN) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Silence Therapeutics stock, see the SLN Stock Forecast page.

Silence Therapeutics Reports Q2 2025 Progress and Financials

Silence Therapeutics is a global clinical-stage biotechnology company focused on developing innovative siRNA therapies to target and silence disease-associated genes, particularly in the liver, with a focus on areas of high unmet medical need such as cardiovascular disease, hematology, and rare diseases.